What is 505(b)(2)?
The 505(b)(2) new drug application (NDA) is one of three U.S. Food and Drug Administration (FDA) drug approval pathways and represents an appealing regulatory strategy for many clients. A 505(b)(2) NDA contains full safety and effectiveness reports but allows at least some of the information required for NDA approval, such as safety and efficacy information on the active ingredient, to come from studies not conducted by or for the applicant. This can result in a much less expensive and much faster route to approval, compared with a traditional development path, such as 505(b)(1), while creating new, differentiated products with tremendous commercial value.
Download our guide to learn about the 505(b)(2) pathway, the types of programs for which it is a good fit, its benefits, and some keys to navigating its regulatory nuances.